Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in hospitalized COVID-19 patients
NCT04346199Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Countries
- 14
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Jun 2020; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04346199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346199.